Breast cancer chemoprevention: Current perspectives

Current Enzyme Inhibition

Volumn 5, Issue 4, 2009, Pages 198-208

  Oyama, Takeru ^a   Yasui, Yumiko ^a   Tanaka, Takuji ^a,b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b Tohkai Cytopathology Institute: Cancer Research and Prevention   (Japan)

Author keywords

Aromatase inhibitors; Breast cancer; Chemoprevention; Prevention trials; SERMs; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; AZACITIDINE; BEXAROTENE; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FENRETINIDE; GENISTEIN; ISOFLAVONE; LAPATINIB; LARZOXIFENE; LIMONENE; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PERILLYL ALCOHOL; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG SCREENING; ENDOMETRIUM CANCER; FRACTURE; GENE MUTATION; HUMAN; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 73449112983     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340809789630271     Document Type: Review

References (143)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55, 74-108.
2. Hortobagyi, G.N. Treatment of breast cancer. N. Engl. J. Med., 1998, 339, 974-984.
3. Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; Thun, M. Cancer Statistics, 2001. CA Cancer J. Clin., 2001, 51, 15-36.
4. Eliassen, A.H.; Colditz, G.A.; Rosner, B.; Willett, W.C.; Hankinson, S.E. Adult weight change and risk of postmenopausal breast cancer. JAMA, 2006, 296, 193-201.
5. Bernstein, L.; Patel, A.V.; Ursin, G.; Sullivan-Halley, J.; Press, M.F.; Deapen, D.; Berlin, J.A.; Daling, J.R.; McDonald, J.A.; Norman, S.A.; Malone, K.E.; Strom, B.L.; Liff, J.; Folger, S.G.; Simon, M.S.; Burkman, R.T.; Marchbanks, P.A.; Weiss, L.K.; Spirtas, R. Lifetime recreational exercise activity and breast cancer risk among black women and white women. J. Natl. Cancer Inst., 2005, 97, 1671-1679.
6. Cuzick, J. Chemoprevention of breast cancer. Breast Cancer, 2008, 15, 10-16.
7. Cuzick, J.; Forbes, J.F.; Howell, A. Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst., 2006, 98, 643; author reply 643-644.
8. Cuzick, J.; Forbes, J.F.; Sestak, I.; Cawthorn, S.; Hamed, H.; Holli, K.; Howell, A. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J. Natl. Cancer Inst., 2007, 99, 272-282.
9. Freedman, A.N.; Graubard, B.I.; Rao, S.R.; McCaskill-Stevens, W.; Ballard-Barbash, R.; Gail, M.H. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl. Cancer Inst., 2003, 95, 526-532.
10. Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.; Sahmoud, T. Anastrozole alone or in combination with tamoxifen vs. tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 2002, 359, 2131-2139.
11. Wolfe, J.N. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer, 1976, 37, 2486-2492.
12. Warner, E.; Lockwood, G.; Tritchler, D.; Boyd, N.F. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect. Prev., 1992, 16, 67-72.
13. Brisson, J.; Diorio, C.; Masse, B. Wolfe's parenchymal pattern and percentage of the breast with mammographic densities: redundant or complementary classifications? Cancer Epidemiol. Biomarkers Prev., 2003, 12, 728-732.
14. Boyd, N.F.; Byng, J.W.; Jong, R.A.; Fishell, E.K.; Little, L.E.; Miller, A.B.; Lockwood, G.A.; Tritchler, D.L.; Yaffe, M.J. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J. Natl. Cancer Inst., 1995, 87, 670-675.
15. Boyd, N.F.; Guo, H.; Martin, L.J.; Sun, L.; Stone, J.; Fishell, E.; Jong, R.A.; Hislop, G.; Chiarelli, A.; Minkin, S.; Yaffe, M.J. Mammographic density and the risk and detection of breast cancer. N. Engl. J. Med., 2007, 356, 227-236.
16. Cuzick, J.; Warwick, J.; Pinney, E.; Warren, R.M.; Duffy, S.W. Tamoxifen and breast density in women at increased risk of breast cancer. J. Natl. Cancer Inst., 2004, 96, 621-628.
17. Greendale, G.A.; Reboussin, B.A.; Slone, S.; Wasilauskas, C.; Pike, M.C.; Ursin, G. Postmenopausal hormone therapy and change in mammographic density. J. Natl. Cancer Inst., 2003, 95, 30-37.
18. Tanaka, T. Chemoprevention of human cancer: biology and therapy. Crit. Rev. Oncol. Hematol., 1997, 25, 139-174.
19. Berenblum, I.; Shubik, P. A new, quantitative, approach to the study of the stages of chemical cartinogenesis in the mouse's skin. Br. J. Cancer, 1947, 1, 383-391.
20. Foulds, L. The experimental study of tumor progression: a review. Cancer Res., 1954, 14, 327-339.
21. Tanaka, T. Effect of diet on human carcinogenesis. Crit. Rev. Oncol. Hematol., 1997, 25, 73-95.
22. Sporn, M.B.; Newton, D.L. Chemoprevention of cancer with retinoids. Fed. Proc., 1979, 38, 2528-2534.
23. Hong, W.K.; Sporn, M.B. Recent advances in chemoprevention of cancer. Science, 1997, 278, 1073-1077.
24. Allred, D.C.; Mohsin, S.K.; Fuqua, S.A. Histological and biological evolution of human premalignant breast disease. Endocrinol. Relat. Cancer, 2001, 8, 47-61.
25. Yang, X.; Lippman, M.E. BRCA1 and BRCA2 in breast cancer. Breast Cancer Res. Treat., 1999, 54, 1-10.
26. Ford, D.; Easton, D.F.; Stratton, M.; Narod, S.; Goldgar, D.; Devilee, P.; Bishop, D.T.; Weber, B.; Lenoir, G.; Chang-Claude, J.; Sobol, H.; Teare, M.D.; Struewing, J.; Arason, A.; Scherneck, S.; Peto, J.; Rebbeck, T.R.; Tonin, P.; Neuhausen, S.; Barkardottir, R.; Eyfjord, J.; Lynch, H.; Ponder, B.A.; Gayther, S.A.; Zelada-Hedman, M. and the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet., 1998, 62, 676-689.
27. Struewing, J.P.; Hartge, P.; Wacholder, S.; Baker, S.M.; Berlin, M.; McAdams, M.; Timmerman, M.M.; Brody, L.C.; Tucker, M.A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 1997, 336, 1401-1408.
28. Malkin, D.; Li, F.P.; Strong, L.C.; Fraumeni, J.F., Jr.; Nelson, C.E.; Kim, D.H.; Kassel, J.; Gryka, M.A.; Bischoff, F.Z.; Tainsky, M.A.; et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 1990, 250, 1233-1238.
29. MacMahon, B.; Cole, P.; Lin, T.M.; Lowe, C.R.; Mirra, A.P.; Ravnihar, B.; Salber, E.J.; Valaoras, V.G.; Yuasa, S. Age at first birth and breast cancer risk. Bull. World Health Organ., 1970, 43, 209-221.
30. Trichopoulos, D.; MacMahon, B.; Cole, P. Menopause and breast cancer risk. J. Natl. Cancer Inst., 1972, 48, 605-613.
31. Newcomb, P.A.; Storer, B.E.; Longnecker, M.P.; Mittendorf, R.; Greenberg, E.R.; Clapp, R.W.; Burke, K.P.; Willett, W.C.; MacMahon, B. Lactation and a reduced risk of premenopausal breast cancer. N. Engl. J. Med., 1994, 330, 81-87.
32. Sillero-Arenas, M.; Delgado-Rodriguez, M.; Rodigues-Canteras, R.; Bueno-Cavanillas, A.; Galvez-Vargas, R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet. Gynecol., 1992, 79, 286-294.
33. Steinberg, K.K.; Thacker, S.B.; Smith, S.J.; Stroup, D.F.; Zack, M.M.; Flanders, W.D.; Berkelman, R.L. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA, 1991, 265, 1985-1990.
34. Meirik, O.; Lund, E.; Adami, H.O.; Bergstrom, R.; Christoffersen, T.; Bergsjo, P. Oral contraceptives and breast cancer. Lancet, 1986, 2, 1272-1273.
35. Page, D.L.; Dupont, W.D. Indicators of increased breast cancer risk in humans. J. Cell Biochem. Suppl., 1992, 16G, 175-182.
36. Grooff, P.N.; Pamies, R.J.; Hunyadi, S. Lobular carcinoma in situ: what clinicians need to know. Hosp. Pract. (Off. Ed.), 1993, 28, 129-130.
37. Gail, M.H.; Brinton, L.A.; Byar, D.P.; Corle, D.K.; Green, S.B.; Schairer, C.; Mulvihill, J.J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst., 1989, 81, 1879-1886.
38. Bondy, M.L.; Lustbader, E.D.; Halabi, S.; Ross, E.; Vogel, V.G. Validation of a breast cancer risk assessment model in women with a positive family history. J. Natl. Cancer Inst., 1994, 86, 620-625.
39. Spiegelman, D.; Colditz, G.A.; Hunter, D.; Hertzmark, E. Validation of the Gail et al. model for predicting individual breast cancer risk. J. Natl. Cancer Inst., 1994, 86, 600-607.
40. Dunning, A.M.; Healey, C.S.; Pharoah, P.D.; Teare, M.D.; Ponder, B.A.; Easton, D.F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 1999, 8, 843-854.
41. Miyoshi, Y.; Iwao, K.; Ikeda, N.; Egawa, C.; Noguchi, S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur. J. Cancer, 2000, 36, 2375-2379.
42. Miyoshi, Y.; Iwao, K.; Ikeda, N.; Egawa, C.; Noguchi, S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int. J. Cancer, 2000, 89, 325-328.
43. Miyoshi, Y.; Takahashi, Y.; Egawa, C.; Noguchi, S. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J., 2002, 8, 209-215.
44. Dunn, B.K.; Ford, L.G. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J., 2001, 7, 144-157.
45. Baylin, S.B.; Herman, J.G.; Graff, J.R.; Vertino, P.M.; Issa, J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 1998, 72, 141-196.
46. Graff, J.R.; Herman, J.G.; Lapidus, R.G.; Chopra, H.; Xu, R.; Jarrard, D.F.; Isaacs, W.B.; Pitha, P.M.; Davidson, N.E.; Baylin, S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res., 1995, 55, 5195-5199.
47. Woodcock, D.M.; Linsenmeyer, M.E.; Doherty, J.P.; Warren, W.D. DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br. J. Cancer, 1999, 79, 251-256.
48. Mancini, D.N.; Rodenhiser, D.I.; Ainsworth, P.J.; O'Malley, F.P.; Singh, S.M.; Xing, W.; Archer, T.K. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene, 1998, 16, 1161-1169.
49. Ottaviano, Y.L.; Issa, J.P.; Parl, F.F.; Smith, H.S.; Baylin, S.B.; Davidson, N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res., 1994, 54, 2552-2555.
50. Lapidus, R.G.; Ferguson, A.T.; Ottaviano, Y.L.; Parl, F.F.; Smith, H.S.; Weitzman, S.A.; Baylin, S.B.; Issa, J.P.; Davidson, N.E. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res., 1996, 2, 805-810.
51. Sirchia, S.M.; Ferguson, A.T.; Sironi, E.; Subramanyan, S.; Orlandi, R.; Sukumar, S.; Sacchi, N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene, 2000, 19, 1556-1563.
52. Yang, X.; Yan, L.; Davidson, N.E. DNA methylation in breast cancer. Endocrinol. Relat. Cancer, 2001, 8, 115-127.
53. Miyoshi, Y.; Iwao, K.; Egawa, C.; Noguchi, S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer, 2001, 92, 370-373.
54. Tanaka, T.; Kimura, M.; Matsunaga, K.; Fukada, D.; Mori, H.; Okano, Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res., 1999, 59, 2041-2044.
55. Rosfjord, E.C.; Dickson, R.B. Growth factors, apoptosis, and survival of mammary epithelial cells. J. Mammary Gland Biol. Neoplasia, 1999, 4, 229-237.
56. Schroeder, W.; Biesterfeld, S.; Zillessen, S.; Rath, W. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res., 1997, 17, 2799-2802.
57. Fabian, C.J.; Zalles, C.; Kamel, S.; Zeiger, S.; Simon, C.; Kimler, B.F. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials. J. Cell Biochem. Suppl., 1997, 28-29, 101-110.
58. Allred, D.C.; Clark, G.M.; Elledge, R.; Fuqua, S.A.; Brown, R.W.; Chamness, G.C.; Osborne, C.K.; McGuire, W.L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 1993, 85, 200-206.
59. Thor, A.D.; Moore, D.H., II; Edgerton, S.M.; Kawasaki, E.S.; Reihsaus, E.; Lynch, H.T.; Marcus, J.N.; Schwartz, L.; Chen, L.C.; Mayall, B.H.; et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 1992, 84, 845-855.
60. Rohan, T.E.; Hartwick, W.; Miller, A.B.; Kandel, R.A. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J. Natl. Cancer Inst., 1998, 90, 1262-1269.
61. Chrysogelos, S.A.; Dickson, R.B. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res. Treat., 1994, 29, 29-40.
62. Sundaresan, S.; Roberts, P.E.; King, K.L.; Sliwkowski, M.X.; Mather, J.P. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology, 1998, 139, 4756-4764.
63. Pegram, M.D.; Finn, R.S.; Arzoo, K.; Beryt, M.; Pietras, R.J.; Slamon, D.J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 1997, 15, 537-547.
64. Vadlamudi, R.; Mandal, M.; Adam, L.; Steinbach, G.; Mendelsohn, J.; Kumar, R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene, 1999, 18, 305-314.
65. Soslow, R.A.; Dannenberg, A.J.; Rush, D.; Woerner, B.M.; Khan, K.N.; Masferrer, J.; Koki, A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 2000, 89, 2637-2645.
66. Mazhar, D.; Ang, R.; Waxman, J. COX inhibitors and breast cancer. Br. J. Cancer, 2006, 94, 346-350.
67. Lanza-Jacoby, S.; Miller, S.; Flynn, J.; Gallatig, K.; Daskalakis, C.; Masferrer, J.L.; Zweifel, B.S.; Sembhi, H.; Russo, I.H. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol. Biomarkers Prev., 2003, 12, 1486-1491.
68. Howe, L.R.; Subbaramaiah, K.; Brown, A.M.; Dannenberg, A.J. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrinol. Relat. Cancer, 2001, 8, 97-114.
69. Parrett, M.L.; Abou-Issa, H.M.; Alshafie, G.; Ross, M.S.; Harris, R.E.; Robertson, F.M. Comparative ability of ibuprofen and N-(4-hydroxyphenyl) retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms. Anticancer Res., 1999, 19, 5079-5085.
70. Subbaramaiah, K.; Telang, N.; Ramonetti, J.T.; Araki, R.; DeVito, B.; Weksler, B.B.; Dannenberg, A.J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res., 1996, 56, 4424-4429.
71. Liu, C.H.; Chang, S.H.; Narko, K.; Trifan, O.C.; Wu, M.T.; Smith, E.; Haudenschild, C.; Lane, T.F.; Hla, T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem., 2001, 276, 18563-18569.
72. Erickson, B.A.; Longo, W.E.; Panesar, N.; Mazuski, J.E.; Kaminski, D.L. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J. Surg. Res., 1999, 81, 101-107.
73. Zhou, J.; Gurates, B.; Yang, S.; Sebastian, S.; Bulun, S.E. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res., 2001, 61, 2328-2334.
74. Bulun, S.E.; Price, T.M.; Aitken, J.; Mahendroo, M.S.; Simpson, E.R. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab., 1993, 77, 1622-1628.
75. Stoll, B.A. Breast cancer: further metabolic-endocrine risk markers? Br. J. Cancer, 1997, 76, 1652-1654.
76. Valentinis, B.; Morrione, A.; Peruzzi, F.; Prisco, M.; Reiss, K.; Baserga, R. Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion. Oncogene, 1999, 18, 1827-1836.
77. Mira, E.; Manes, S.; Lacalle, R.A.; Marquez, G.; Martinez, A.C. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology, 1999, 140, 1657-1664.
78. Clarke, R.B.; Howell, A.; Anderson, E. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br. J. Cancer, 1997, 75, 251-257.
79. Hankinson, S.E.; Willett, W.C.; Colditz, G.A.; Hunter, D.J.; Michaud, D.S.; Deroo, B.; Rosner, B.; Speizer, F.E.; Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 1998, 351, 1393-1396.
80. Decensi, A.; Robertson, C.; Ballardini, B.; Paggi, D.; Guerrieri-Gonzaga, A.; Bonanni, B.; Manetti, L.; Johansson, H.; Barreca, A.; Bettega, D.; Costa, A. Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur. J. Cancer, 1999, 35, 596-600.
81. Mommers, E.C.; van Diest, P.J.; Leonhart, A.M.; Meijer, C.J.; Baak, J.P. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum. Pathol., 1998, 29, 1539-1545.
82. Dou, Q.P.; Levin, A.H.; Zhao, S.; Pardee, A.B. Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res., 1993, 53, 1493-1497.
83. Porter, P.L.; Malone, K.E.; Heagerty, P.J.; Alexander, G.M.; Gatti, L.A.; Firpo, E.J.; Daling, J.R.; Roberts, J.M. Expression of cellcycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 1997, 3, 222-225.
84. Faratian, D.; Bartlett, J. Predictive markers in breast cancer--the future. Histopathology, 2008, 52, 91-98.
85. Krishnamurthy, S.; Sneige, N. Molecular and biologic markers of premalignant lesions of human breast. Adv. Anat. Pathol., 2002, 9, 185-197.
86. Levenson, V.V. Biomarkers for early detection of breast cancer: what, when, and where? Biochim. Biophys. Acta, 2007, 1770, 847-856.
87. Brisson, J.; Berube, S.; Diorio, C. Breast density: a biomarker to better understand and prevent breast cancer. Bull Cancer, 2006, 93, 847-855.
88. Mitlak, B.H.; Cohen, F.J. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm. Res., 1997, 48, 155-163.
89. Baker, V.L.; Jaffe, R.B. Clinical uses of antiestrogens. Obstet. Gynecol. Surv., 1996, 51, 45-59.
90. Furr, B.J.; Jordan, V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther,. 1984, 25, 127-205.
91. Cuzick, J.; Baum, M. Tamoxifen and contralateral breast cancer. Lancet, 1985, 2, 282.
92. Conney, A.H. Tailoring cancer chemoprevention regimens to the individual. J. Cell Biochem., 2004, 91, 277-286.
93. Pappas, S.G.; Jordan, V.C. Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev., 2002, 21, 311-321.
94. Cuzick, J.; Wang, D.Y.; Bulbrook, R.D. The prevention of breast cancer. Lancet, 1986, 1, 83-86.
95. Cuzick, J.; Powles, T.; Veronesi, U.; Forbes, J.; Edwards, R.; Ashley, S.; Boyle, P. Overview of the main outcomes in breast-cancer prevention trials. Lancet, 2003, 361, 296-300.
96. Powles, T.J.; Ashley, S.; Tidy, A.; Smith, I.E.; Dowsett, M. Twenty-year follow-up of the Royal Marsden randomized, doubleblinded tamoxifen breast cancer prevention trial. J. Natl. Cancer Inst., 2007, 99, 283-290.
97. Brzozowski, A.M.; Pike, A.C.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G.L.; Gustafsson, J.A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 1997, 389, 753-758.
98. Ettinger, B.; Black, D.M.; Mitlak, B.H.; Knickerbocker, R.K.; Nickelsen, T.; Genant, H.K.; Christiansen, C.; Delmas, P.D.; Zanchetta, J.R.; Stakkestad, J.; Gluer, C.C.; Krueger, K.; Cohen, F.J.; Eckert, S.; Ensrud, K.E.; Avioli, L.V.; Lips, P.; Cummings, S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, 282, 637-645.
99. Cummings, S.R.; Eckert, S.; Krueger, K.A.; Grady, D.; Powles, T.J.; Cauley, J.A.; Norton, L.; Nickelsen, T.; Bjarnason, N.H.; Morrow, M.; Lippman, M.E.; Black, D.; Glusman, J.E.; Costa, A.; Jordan, V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 1999, 281, 2189-2197.
100. Martino, S.; Cauley, J.A.; Barrett-Connor, E.; Powles, T.J.; Mershon, J.; Disch, D.; Secrest, R.J.; Cummings, S.R. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst., 2004, 96, 1751-1761.
101. Barrett-Connor, E.; Mosca, L.; Collins, P.; Geiger, M.J.; Grady, D.; Kornitzer, M.; McNabb, M.A.; Wenger, N.K. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med., 2006, 355, 125-137.
102. Vogel, V.G.; Costantino, J.P.; Wickerham, D.L.; Cronin, W.M.; Cecchini, R.S.; Atkins, J.N.; Bevers, T.B.; Fehrenbacher, L.; Pajon, E.R., Jr.; Wade, J.L., 3rd; Robidoux, A.; Margolese, R.G.; James, J.; Lippman, S.M.; Runowicz, C.D.; Ganz, P.A.; Reis, S.E.; McCaskill-Stevens, W.; Ford, L.G.; Jordan, V.C.; Wolmark, N. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, 295, 2727-2741.
103. O'Regan, R.M.; Jordan, V.C. Tamoxifen to raloxifene and beyond. Semin. Oncol., 2001, 28, 260-273.
104. Jordan, V.C.; Morrow, M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocrinol. Rev., 1999, 20, 253-278.
105. Boccardo, F.; Rubagotti, A.; Puntoni, M.; Guglielmini, P.; Amoroso, D.; Fini, A.; Paladini, G.; Mesiti, M.; Romeo, D.; Rinaldini, M.; Scali, S.; Porpiglia, M.; Benedetto, C.; Restuccia, N.; Buzzi, F.; Franchi, R.; Massidda, B.; Distante, V.; Amadori, D.; Sismondi, P. Switching to anastrozole vs. continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol., 2005, 23, 5138-5147.
106. Coates, A.S.; Keshaviah, A.; Thurlimann, B.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Colleoni, M.; Lang, I.; Del Mastro, L.; Smith, I.; Chirgwin, J.; Nogaret, J.M.; Pienkowski, T.; Wardley, A.; Jakobsen, E.H.; Price, K.N.; Goldhirsch, A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol., 2007, 25, 486-492.
107. Coombes, R.C.; Kilburn, L.S.; Snowdon, C.F.; Paridaens, R.; Coleman, R.E.; Jones, S.E.; Jassem, J.; Van de Velde, C.J.; Delozier, T.; Alvarez, I.; Del Mastro, L.; Ortmann, O.; Diedrich, K.; Coates, A.S.; Bajetta, E.; Holmberg, S.B.; Dodwell, D.; Mickiewicz, E.; Andersen, J.; Lonning, P.E.; Cocconi, G.; Forbes, J.; Castiglione, M.; Stuart, N.; Stewart, A.; Fallowfield, L.J.; Bertelli, G.; Hall, E.; Bogle, R.G.; Carpentieri, M.; Colajori, E.; Subar, M.; Ireland, E.; Bliss, J.M. Survival and safety of exemestane vs. tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 2007, 369, 559-570.
108. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Therasse, P.; Palmer, M.J.; Pater, J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med., 2003, 349, 1793-1802.
109. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 2005, 365, 60-62.
110. Jakesz, R.; Jonat, W.; Gnant, M.; Mittlboeck, M.; Greil, R.; Tausch, C.; Hilfrich, J.; Kwasny, W.; Menzel, C.; Samonigg, H.; Seifert, M.; Gademann, G.; Kaufmann, M.; Wolfgang, J. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 2005, 366, 455-462.
111. Eastell, R.; Hannon, R.A.; Cuzick, J.; Dowsett, M.; Clack, G.; Adams, J.E. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J. Bone Miner. Res., 2006, 21, 1215-1223.
112. Torrisi, R.; Decensi, A.; Formelli, F.; Camerini, T.; De Palo, G. Chemoprevention of breast cancer with fenretinide. Drugs, 2001, 61, 909-918.
113. Brown, P.H.; Lippman, S.M. Chemoprevention of breast cancer. Breast Cancer Res. Treat., 2000, 62, 1-17.
114. Moon, R.C.; Thompson, H.J.; Becci, P.J.; Grubbs, C.J.; Gander, R.J.; Newton, D.L.; Smith, J.M.; Phillips, S.L.; Henderson, W.R.; Mullen, L.T.; Brown, C.C.; Sporn, M.B. N-(4-Hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res., 1979, 39, 1339-1346.
115. Torrisi, R.; Parodi, S.; Fontana, V.; Pensa, F.; Casella, C.; Barreca, A.; De Palo, G.; Costa, A.; Decensi, A. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int. J. Cancer, 1998, 76, 787-790.
116. Veronesi, U.; De Palo, G.; Marubini, E.; Costa, A.; Formelli, F.; Mariani, L.; Decensi, A.; Camerini, T.; Del Turco, M.R.; Di Mauro, M.G.; Muraca, M.G.; Del Vecchio, M.; Pinto, C.; D'Aiuto, G.; Boni, C.; Campa, T.; Magni, A.; Miceli, R.; Perloff, M.; Malone, W.F.; Sporn, M.B. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst., 1999, 91, 1847-1856.
117. Gottardis, M.M.; Bischoff, E.D.; Shirley, M.A.; Wagoner, M.A.; Lamph, W.W.; Heyman, R.A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res., 1996, 56, 5566-5570.
118. Bischoff, E.D.; Gottardis, M.M.; Moon, T.E.; Heyman, R.A.; Lamph, W.W. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res., 1998, 58, 479-484.
119. Egan, K.M.; Stampfer, M.J.; Giovannucci, E.; Rosner, B.A.; Colditz, G.A. Prospective study of regular aspirin use and the risk of breast cancer. J. Natl. Cancer Inst., 1996, 88, 988-993.
120. Sharpe, C.R.; Collet, J.P.; McNutt, M.; Belzile, E.; Boivin, J.F.; Hanley, J.A. Nested case-control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage. Br. J. Cancer, 2000, 83, 112-120.
121. Tan, W.C.; Privett, O.S.; Goldyne, M.E. Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. Cancer Res., 1974, 34, 3229-3231.
122. Bennett, A.; Charlier, E.M.; McDonald, A.M.; Simpson, J.S.; Stamford, I.F.; Zebro, T. Prostaglandins and breast cancer. Lancet, 1977, 2, 624-626.
123. Liu, X.H.; Rose, D.P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res., 1996, 56, 5125-5127.
124. Alshafie, G.A.; Abou-Issa, H.M.; Seibert, K.; Harris, R.E. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol. Rep., 2000, 7, 1377-1381.
125. Nakatsugi, S.; Ohta, T.; Kawamori, T.; Mutoh, M.; Tanigawa, T.; Watanabe, K.; Sugie, S.; Sugimura, T.; Wakabayashi, K. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn. J. Cancer Res., 2000, 91, 886-892.
126. Rahme, E.; Ghosn, J.; Dasgupta, K.; Rajan, R.; Hudson, M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer, 2005, 5, 159.
127. Swede, H.; Mirand, A.L.; Menezes, R.J.; Moysich, K.B. Association of regular aspirin use and breast cancer risk. Oncology, 2005, 68, 40-47.
128. Harris, R.E.; Beebe-Donk, J.; Alshafie, G.A. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer, 2006, 6, 27.
129. Wu, K.; Zhang, Y.; Xu, X.C.; Hill, J.; Celestino, J.; Kim, H.T.; Mohsin, S.K.; Hilsenbeck, S.G.; Lamph, W.W.; Bissonette, R.; Brown, P.H. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res., 2002, 62, 6376-6380.
130. Bonovas, S.; Filioussi, K.; Tsavaris, N.; Sitaras, N.M. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol., 2005, 23, 8606-8612.
131. Cauley, J.A.; Zmuda, J.M.; Lui, L.Y.; Hillier, T.A.; Ness, R.B.; Stone, K.L.; Cummings, S.R.; Bauer, D.C. Lipid-lowering drug use and breast cancer in older women: a prospective study. J. Womens Health (Larchmt), 2003, 12, 749-756.
132. Eliassen, A.H.; Colditz, G.A.; Rosner, B.; Willett, W.C.; Hankinson, S.E. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch. Intern. Med., 2005, 165, 2264-2271.
133. Gould, M.N. Prevention and therapy of mammary cancer by monoterpenes. J. Cell Biochem. Suppl., 1995, 22, 139-144.
134. Oates, A.J.; Schumaker, L.M.; Jenkins, S.B.; Pearce, A.A.; DaCosta, S.A.; Arun, B.; Ellis, M.J. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res. Treat., 1998, 47, 269-281.
135. Ripple, G.H.; Gould, M.N.; Stewart, J.A.; Tutsch, K.D.; Arzoomanian, R.Z.; Alberti, D.; Feierabend, C.; Pomplun, M.; Wilding, G.; Bailey, H.H. Phase I clinical trial of perillyl alcohol administered daily. Clin. Cancer Res., 1998, 4, 1159-1164.
136. Barnes, S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res. Treat., 1997, 46, 169-179.
137. Lantry, L.E.; Zhang, Z.; Yao, R.; Crist, K.A.; Wang, Y.; Ohkanda, J.; Hamilton, A.D.; Sebti, S.M.; Lubet, R.A.; You, M. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis, 2000, 21, 113-116.
138. Ferguson, A.T.; Lapidus, R.G.; Baylin, S.B.; Davidson, N.E. Demethylation of the estrogen receptor gene in estrogen receptornegative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res., 1995, 55, 2279-2283.
139. Jenkins, V.A.; Ambroisine, L.M.; Atkins, L.; Cuzick, J.; Howell, A.; Fallowfield, L.J. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol., 2008, 9, 953-961.
140. Richardson, H.; Johnston, D.; Pater, J.; Goss, P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr. Oncol., 2007, 14, 89-96.
141. Meyskens, F.L., Jr.; Gerner, E.W. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res., 1999, 5, 945-951.
142. Herbert, B.S.; Wright, A.C.; Passons, C.M.; Wright, W.E.; Ali, I.U.; Kopelovich, L.; Shay, J.W. Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J. Natl. Cancer Inst., 2001, 93, 39-45.
143. Fan, S.; Wang, J.; Yuan, R.; Ma, Y.; Meng, Q.; Erdos, M.R.; Pestell, R.G.; Yuan, F.; Auborn, K.J.; Goldberg, I.D.; Rosen, E.M. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science, 1999, 284, 1354-1356.